Cancer Genomics Laboratory

Group leader: Per Guldberg

Our group is interested in understanding the genomic alterations that drive cancer development, with a focus on DNA testing for early and non-invasive detection of cancer.

We are involved in the development and use of technologies for high-sensitivity detection of mutations, DNA methylation and other genomic alterations that can be used as specific biomarkers for cancer. Recent work includes the development of urine-based tests for detection of bladder cancer and other genitourinary cancers.

Per Guldberg

Per Guldberg

After obtaining a MS in Molecular Biology from the University of Copenhagen, I moved to the John F. Kennedy Institute, where my thesis involved the molecular characterization of phenylketonuria and other inherited genetic disorders.

In 1994, I started as a postdoc at the Danish Cancer Society, where I got interested in somatic genetic and epigenetic alterations in cancer as well as technologies for detecting these alterations. I have been a Group Leader since 2002.

Group members

Postdoc Christina Dahl
PhD student Louise Katrine Larsen

Five selected publications:

Christensen, C., Bartkova, J., Mistrik, M., Hall, A., Lange, M. K., Ralfkiær, U., Bartek, J., Guldberg, P.
A short acidic motif in ARF guards against mitochondrial dysfunction and melanoma susceptibility.
Nat.Commun. 2014: 5, 5348

Dahl, C., Abildgaard, C., Riber-Hansen, R., Steiniche, T., Lade-Keller, J., Guldberg, P.
KIT is a frequent target for epigenetic silencing in cutaneous melanoma.
J.Invest Dermatol. 2015: 135(2), 516-524

Dahmcke, C. M., Steven, K. E., Larsen, L. K., Poulsen, A. L., Abdul-Al, A., Dahl, C., Guldberg, P.
A prospective blinded evaluation of urine-DNA testing for detection of urothelial bladder carcinoma in patients with gross hematuria.
Eur.Urol. 2016: 70(6), 916-919

Abildgaard, C., Dahl, C., Abdul-Al, A., Christensen, A., Guldberg, P.
Inhibition of retinoic acid receptor beta signaling confers glycolytic dependence and sensitization to dichloroacetate in melanoma cells.
Oncotarget. 2017: 8(48), 84210-84223

Kirkin, A. F., Dzhandzhugazyan, K. N., Guldberg, P., Fang, J. J., Andersen, R. S., Dahl, C., Mortensen, J., Lundby, T., Wagner, A., Law, I., Broholm, H., Madsen, L., Lundell-Ek, C., Gjerstorff, M. F., Ditzel, H. J., Jensen, M. R., Fischer, W.
Adoptive cancer immunotherapy using DNA-demethylated T helper cells as antigen-presenting cells.
Nat.Commun. 2018: 9(1), 785

ORCID:

Per Guldberg

0000-0002-4424-4803